The Effect of 12-Week Dietary Intake of Lutein on Minimal Erythema Dose and Other Skin Parameters

NCT ID: NCT03811977

Last Updated: 2019-09-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-04

Study Completion Date

2019-08-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The double-center, randomized, placebo-controlled, one-period effectiveness study will include 30 subjects (women, aged between 25 to 55 years, Fitzpatrick phototype II and III). Subjects will be divided in two groups, 15 in each. One group (test group) will receive investigational product - lutein syrup (4 mg/mL; daily dose 20 mg) and the other (placebo group) placebo syrup. Participants will test continuous administration of placebo or investigational product for 12 weeks in order to demonstrate and assess multiple-dose effects. The primary objective is to assess the photoprotective potential of the investigational product in relation to placebo product. The secondary objectives are to assess effects of investigational product on dermis density and skin viscoelasticity after 12 weeks of dietary supplementation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Minimal Erythema Dose Skin Viscoelasticity Dermis Density

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Test group

Test group will receive investigational product - lutein syrup (2 mg/mL; daily dose 20 mg). Participants in this group will test continuous administration of investigational product for 12 weeks.

Group Type EXPERIMENTAL

Lutein syrup

Intervention Type DIETARY_SUPPLEMENT

12- week dietary supplementation with lutein syrup (20 mg lutein/day)

Placebo group

Placebo group will receive placebo product - placebo syrup (lutein 0 mg/mL; daily dose 0 mg). Continuous administration of placebo product for 12 weeks.

Group Type PLACEBO_COMPARATOR

Placebo syrup

Intervention Type DIETARY_SUPPLEMENT

12- week dietary supplementation with placebo syrup (0 mg lutein/day)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lutein syrup

12- week dietary supplementation with lutein syrup (20 mg lutein/day)

Intervention Type DIETARY_SUPPLEMENT

Placebo syrup

12- week dietary supplementation with placebo syrup (0 mg lutein/day)

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Caucasian female volunteers aged between 25 and 55 years at the time of the signature of Informed consent form (ICF),
* Signed Informed consent form (ICF),
* Fitzpatrick skin phototypes II and III,
* No skin pigmentation disorders,
* In good health condition,
* Willingness to avoid a consumption of any food supplements containing carotenes or other antioxidants during the study,
* Willingness to avoid the sun, tanning beds and tanning products on the gluteal area during the study,
* Willingness to follow all study procedures and keeping a diary for during the study (to follow their compliance and palatability),
* No changes in dietary habits or dietary supplements in last month prior to inclusion.
* No changes in cosmetic facial and body care routine in last month prior to inclusion on measurement areas.

Exclusion Criteria

* Pregnancy or breastfeeding,
* Known or suspected allergy to any ingredient of the tested products or UV radiation,
* Changes in dietary habits and dietary supplementation in last month prior to inclusion,
* Veganism,
* Changes in cosmetic facial and body care routine in last month prior to inclusion.
* Diagnosed and uncontrolled/untreated/unregulated disease,
* Any clinically significant history of serious metabolic disease, digestive tract disease, liver disease, kidney disease, haematological disease.
* Acute skin diseases,
* Regular consumption of food supplements containing carotenoids or other antioxidants in last month before inclusion into the study.
* Invasive rejuvenation treatments (e.g. needle rollers, needle mesotherapy, deep/medium-deep chemical peels etc.) in last 6 months prior to study entry,
* Non-invasive rejuvenation treatments (e.g. radiofrequency, electrotherapy, ultrasound therapy) in last 2 months prior to study entry,
* Gluteal hyperpigmentation,
* Mental incapacity that precludes adequate understanding or cooperation
Minimum Eligible Age

25 Years

Maximum Eligible Age

55 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

European Regional Development Fund

OTHER

Sponsor Role collaborator

Ministry of Education, Science and Sport, Republic of Slovenia

UNKNOWN

Sponsor Role collaborator

Dermatologija Bartenjev Rogl

UNKNOWN

Sponsor Role collaborator

Slovenian Research Agency

OTHER

Sponsor Role collaborator

Valens Int. d.o.o., Slovenija

INDUSTRY

Sponsor Role collaborator

VIST - Faculty of Applied Sciences

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Katja Žmitek

Role: STUDY_DIRECTOR

Head of Research Group

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Higher School of Applied Sciences, Institute of Cosmetics

Ljubljana, , Slovenia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Slovenia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VIST F4F Lutein-MED 01-2018

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.